How NAMENDA XR Works
How does NAMENDA XR work?
NAMENDA XR® (memantine hydrochloride) works in a different way than other Alzheimer's disease medications.
That's why adding NAMENDA XR to an AChEI is effective—
2 different treatments working in 2 different ways to treat moderate to
severe Alzheimer's disease.
There are 2 types of medications that are approved to treat the symptoms of Alzheimer's disease:
Glutamate pathway modifiers (NAMENDA XR) and acetylcholinesterase inhibitors (AChEI)
What prescription drug treatment options are available?
There are currently 2 types of prescription medications for Alzheimer's disease.
These medications work differently to treat the symptoms of the disease. Often these
medications are used together in patients with moderate to severe Alzheimer's disease.
- One type of medication is thought to work by slowing the breakdown of a chemical
in the brain called acetylcholine. This chemical is involved in learning and memory.
This type of medication is called an acetylcholinesterase inhibitor (or AChEI).
Examples of this medication include ARICEPT® (donepezil)*,
RAZADYNE® (galantamine)†, and
- Another type of Alzheimer's disease medication may help regulate the abnormal activity
of glutamate in the brain. Glutamate is another chemical in the brain that is important
for learning and memory. NAMENDA XR® (memantine HCI) is a once-a-day medication
of this type approved for moderate to severe Alzheimer's disease, which can be used
alone or added to ongoing AChEI therapy
Because the 2 types of medication work in different ways, taking them together may
be helpful—this is called combination therapy.
There is no evidence that NAMENDA XR or an AChEI prevents or slows the underlying
disease process in patients with Alzheimer's disease.
Find out if it's time to add NAMENDA
XR to an AChEI
discussing NAMENDA XR with your loved one's doctor
*ARICEPT is a registered trademark of Eisai Co., Ltd.
†RAZADYNE is a registered trademark of Johnson & Johnson.
‡EXELON is a registered trademark of Novartis AG Corp.